Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Recombinant super-compound interferon and uses thereof

A compound interferon and high-efficiency technology, applied in the field of bioengineering, can solve problems such as inability to inhibit e and s antigens

Active Publication Date: 2008-03-05
SUPERLAB FAR EAST LTD
View PDF8 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

All interferons can inhibit viral DNA replication, but they cannot inhibit the expression of e and s antigens

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant super-compound interferon and uses thereof
  • Recombinant super-compound interferon and uses thereof
  • Recombinant super-compound interferon and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0136] Effect of Recombinant High-efficiency Composite Interferon (rSIFN-co) on Ebola Virus

[0137] Background: Ebola virus is a deadly virus known to cause horrific symptoms, most notably high fever and widespread bleeding. The fatality rate of Ebola virus infection is 90%. It is one of the viruses that can cause hemorrhagic (bloody) fever. There is no specific cure for this disease. Currently, patients can only receive supportive care. This includes balancing the patient's fluids and electrolytes, maintaining their oxygen levels and blood pressure, and treating any concurrent infections they have. Death can occur within 10 days of onset of symptoms.

[0138] 1. Materials

[0139] 1.1 Drug: rSIFN-co, provided by Sichuan Biotechnology Research Center.

[0140] 1.2 Virus: Ebola virus, provided by the Institute of Microbial Epidemiology, Academy of Military Medical Sciences.

[0141] 1.3 Experimental safety level: Virus experiments are carried out under the level 3 safet...

example 2

[0151] HIV Inhibitory Effect of Recombinant Supercomplex Interferon (rSIFN-co)

[0152] 1. Materials

[0153] 1.1 Wild-type HIV

[0154] 1.2 Drug-resistant HIV

[0155] 1.3 293-CD4-CCRS cells

[0156] 1.4 DEME, Gibco Corporation

[0157] 1.5 FBS, Gibco

[0158] 1.6 rSIFN-co, provided by Sichuan Biotechnology Research Center

[0159] 1.796-well plate, NUNC

[0160] 1.8 carbon dioxide incubator

[0161] 1.9 laminar flow purification hood

[0162] 1.10 Fluorometer

[0163] 1.11 UV absorber

[0164] 1.12 Others

[0165] 2. Method

[0166] 2.1 Obtain 293-CD4-CCR5 cells in the logarithmic growth phase (log), digest with 0.25% trypsin, determine the number of cells with trypan blue staining, and dilute with DMEM to a cell concentration of 2.0×10 per ml 5 (cells / ml).

[0167] 2.2 Add 100 μl (microliter) of 293-CD4-CCR5 suspension in DMEM to each well of the 96-well plate. The orifice plate was placed in a 5% carbon dioxide incubator at 37°C, and seventy percent (70%) of ...

example 3

[0181] Anti-influenza Effect of Recombinant High-efficiency Composite Interferon (rSIFN-co)

[0182] 1. Materials

[0183] 1.1 10-day-old chicken embryo membrane cells

[0184] 1.2 rSIFN-co, provided by Sichuan Biotechnology Research Center

[0185] 1.3 Influenza virus, provided by the Molecular Biology Laboratory of the Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences.

[0186] 1.4 DMEM, Gibco

[0187] 1.5 newborn calf serum

[0188] 1.6 96-well plates, NUNC

[0189] 1.7 Carbon dioxide incubator

[0190] 1.8 laminar flow purification hood

[0191] 1.9 Inverted Microscope

[0192] 1.10 Others

[0193] 2. Method

[0194] 2.1 Take 10-day-old chick embryonic membrane cells in the logarithmic (log) growth phase, digest with 0.25% trypsin, determine the cell number with trypan blue staining, and dilute with DMEM to a cell concentration of 2.0×10 per ml 5 (cells / ml).

[0195] 2.2 Add 100 μl (microliter) of 293-CD4-CCR5 suspension in DMEM to...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention provides different uses of recombinant super-compound interferons (rSIFN-cos) and its equivalent with changed spatial configuration, high efficacy and low side effects. Therefore, high dose of rSIFN-co may be used. One characteristic of rSIFN-co is its ability to inhibit the HBV DNA duplication and secretion of HBsAg and HBeAg in in vitro pharmacological studies. The cytotoxic effect of rSIFN-co is only one-eighth (1 / 8) of currently clinically available interferons but its anti-viral effect is approximately five to twenty (5-20) times higher, and when used in vivo it has a broader spectrum of clinical applications and longer biofeedback response. This invention further provides super-compound interferon or its equivalent, synthesis of artificial gene with codon preference which codes for said rSIFN-co and its equivalent, vector comprising said gene and appropriate expression system for expression of said rSIFN-co. Finally this invention provides the super-compound interferon (rSIFN-co) and its equivalent, a process to produce same and uses thereof.

Description

[0001] This application is a continuation-in-part of US Patent Application Serial No. 60 / 659,925, filed March 9, 2005; the entirety of which is incorporated herein by reference. [0002] Throughout this application, various publications are cited. The entire disclosure of these publications is incorporated by reference in this application for the purpose of more fully explaining the state of the art to which the present invention pertains. field of invention [0003] The present invention relates to the field of bioengineering. Specifically, the present invention relates to a recombinant high-efficiency composite (super-compound) interferon (rSIFN-co) (rSIFN-co) or its equivalent with altered stereo configuration, high efficacy and low side effects. Therefore, rSIFN-co can be applied at high doses. The present invention also relates to a method for preparing the high-efficiency compound interferon (rSIFN-co) or a pharmaceutical composition containing the high-efficiency comp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/21A61P31/12A61P35/00A61P1/06A61P11/00
CPCA61K9/127A61K38/21A61K38/212C07K14/555A61K9/0019A61P1/06A61P1/16A61P11/00A61P31/12A61P31/14A61P31/16A61P31/18A61P31/22A61P35/00A61P35/02Y02A50/30
Inventor 魏光文
Owner SUPERLAB FAR EAST LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com